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Our objectives were to perform a longitudinal assessment of mental status in early stage Parkinson’s disease (PD) patients, with
brief neuropsychological tests, in order to find predictive factors for cognitive decline. Sixty-one, early stage, and nondemented
patients were assessed twice, over a 2-year interval, with a global cognitive test (mini-mental state examination (MMSE)) and a
frontal function test (frontal assessment battery (FAB)) and motor function scales. Dementia and hallucinations were diagnosed
according to the DSM-IV criteria. Cognitive function scores did not decrease significantly, except for FAB lexical fluency score.
Four patients presented with dementia at followup. The MMSE score below cut-off, worse gait dysfunction, the nontremor motor
subtype, and hallucinations were significantly related to dementia. Rigidity and speech dysfunction were related to dementia and a
decrease in FAB scores.We can conclude that decline in theMMSE and FAB scores is small and heterogeneous in the early stages of
PD. Scores below cut-off in the MMSE could be helpful to predict dementia. Nontremor motor deficits could be predictive factors
for frontal cognitive decline and dementia.
1. Introduction
Parkinson’s disease is a movement disorder, defined by a
combination of tremor, rigidity, bradykinesia, and gait dis-
turbances [1]. Lately, a constellation of nonmotor symptoms
has also been described [2]. Cognitive dysfunction,which can
ultimately lead to dementia in a great number of cases [3], is
a cause of great incapacity in PD. As therapeutic alternatives
develop [4], the need for an early detection of cognitive
deficits and for accurate prediction of cognitive outcome
increases. Brief cognitive tests could be useful for a rapid
screening of patients at higher risk for cognitive decline.
They also could be of use for following cognitive decline
and predicting cognitive outcome. Noncognitive symptoms
at the baseline, like motor dysfunction severity, or specific
motor symptoms could also be useful as cognitive outcome
predictors. Several studies have defined significant clinical
heterogeneity at disease onset [5, 6] which could determine
prognosis. In previous work, we found that early stage,
nondemented PD patients presented with significantly lower
scores in the frontal assessment battery (FAB) and the
mini-mental state examination (MMSE), when compared to
non-PD aged controls, and that MMSE scores were related
to nontremor motor scores [7]. In the present study, our
objectives were to perform a longitudinal analysis of this
cohort, in order to assess the relation between motor and
cognitive performance at baseline and cognitive dysfunction
progression.
2. Methods
Seventy-five early stage PD patients, diagnosed according
to validated criteria [1], were consecutively recruited from
Hospital Egas Moniz Neurology Department’s outpatient
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clinic. Exclusion criteria were the existence of relevant psy-
chiatric, medical or other neurological diseases. The early
stage PD was defined as disease duration (time in years from
appearance of firstmotor symptoms to study first assessment)
up to 5 years and the Hoehn and Yahr [8] (HY) stage from 1
to 2.5, included, at baseline.




), with the same instruments and by the same observer.
2.1.MotorAssessment. Patientswere assessedwith the unified
Parkinson’s disease rating scale (UPDRS) parts II and III
[9], after receiving their usual medication and while on
on state. Separated scores were derived for tremor, rigidity,
bradykinesia, speech, and gait/postural stability symptoms,
from items 20 and 21, 22, 23 to 27, 18, and 29 to 30, respectively.
Patients were split into tremor, intermediate, and postural
instability and gait difficulty (PIGD) predominant motor
groups, according to the classification system proposed by
Jankovic and coworkers [10]. For statistical purposes, this
variable was dichotomized in tremor and nontremor (PIGD
+ intermediate). Dopaminergic treatment was calculated as
L-dopa equivalent doses (DED) [11].
2.2. Cognitive Function Assessment
2.2.1. MMSE. Global cognitive function was evaluated with
the MMSE [12]. The MMSE is a widely used bed-side
test, which assesses orientation, verbal memory, language,
attention/calculation, and visuoconstructive abilities. While
some studies have challenged. MMSE efficacy as a screening
instrument in Parkinson’s disease, because it lacks specific
tests for executive function assessment [13–15], others have
found the MMSE useful to detect cognitive deterioration
in the early stage PD [16] and also a significant correlation
between the MMSE scores and cortical hypometabolism
[17], motor symptoms [18–20], and neuropathological status
[21]. The MMSE has been recommended by the movement
disorder society task force for level I testing, to assess PD
associated with a decreased global cognitive efficiency and
also for detecting impairment in more than one cognitive
domain [22] and has been previously used to characterize pd
dementia in clinical trials [4, 23].
2.2.2. FAB. Frontal function was assessed with the FAB [24].
The frontal assessment battery (FAB) is a rapid screening
battery (taking approximately ten minutes), which evaluates
several frontal function domains (conceptualization, mental
flexibility, motor programming, sensitivity to interference,
inhibitory control, and environmental autonomy), and it has
been validated for PD [25–27]. Studies have shown high
correlation with classical frontal neuropsychological tests
[24], significant differences between patients and controls
[25, 26], and correlation between the FAB performance and
perfusion in the medial and dorsolateral frontal cortex [27].
Portuguese validated versions of the tests were used [28,
29]. We determined the number of patients with global
(MMSE) and frontal (FAB) cognitive dysfunctions, using
published cut-off scores for the Portuguese versions of the
tests [28, 29]. Cut-off scores for theMMSEwere the following:
22 (0 to 2 years of schooling); 24 (3 to 6 years of schooling); 27
(7 ormore years of schooling) (scores below the cut-off scores
were considered as signifying global cognitive dysfunction).
Patients were considered to have frontal dysfunction if they
scored one standard deviation below healthy controls mean
score of the same age group, as presented in the validation
study of the Portuguese version of the test. As reported by the
authors, the normative study involved 122 control subjects (68
women and 54men) who varied widely in age and education.
They were from various regions of Portugal, from urban and
nonurban areas. None of the participants had any conditions
that could affect the mental state, as assessed by an individual
clinical interview.
Given that the instruments were applied by the same
observer in two different time points, it is important to verify
the test-retest variability of the tests and the their intrarater
reliability to make sure that the changes we observe are real
and not influenced by the variability of the test itself. The
validity and reliability of the FAB were confirmed by several
studies [30, 31]. Test-retest reliability (intrarater reliability)
was found to be adequate. Siderowf et al. [32] have validated
the UPDRS and found high intrarater reliability for the total
score of part three and also for the tremor, bradykinesia and
rigidity subscales. The construct validity of these subscales
had been previously verified by McDermott et al. [33].
Validation studies have also confirmed the intrarater and test-
retest reliability of the mini-mental state examination [34].
The study by Aarsland and collaborators [35], performed on
the PD patients, suggests that the MMSE is valid to measure
the change in cognitive state for periods of at least one year.
Dementia and the presence of hallucinations were diag-
nosed according to the DSM-IV-R criteria [36]. Halluci-
nations were defined as a sensory perception that has the
compelling sense of reality of a true perception but that
occurs without external stimulation of the relevant sensory
organ. Dementia was defined, after exclusion of other causes,
as the progressive development of cognitive deficits causing
at least two of the following: memory impairment, language
disturbance, apraxia, agnosia, and disturbance in executive
functioning.The cognitive deficits cause a significant impair-
ment in social or occupational functioning and represent
a significant decline from a previous level of functioning.
We used the incapacity to independently manage the PD
medication as criteria for the significant impact of cognitive
dysfunction in daily live activities, as suggested in [22].
2.3. Data Analysis. The incidence of dementia was calculated
by dividing new cases of dementia by the number of person-
years at risk throughout the observation period. Because it
is not possible to know the precise time a subject became
demented, it was assumed to occur in the midpoint of the
period of observation.
In a first analysis, we compared the differences in the FAB





using paired sample 𝑡-tests or the Wilcoxon tests (depending
on the distribution of the samples). Variations in FAB and
MMSE scores were also calculated for each patient, as
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Table 1: Comparison between patients who remained in observation and those lost for follow-up.
Remained in observation (𝑛 = 61) Lost for follow-up (𝑛 = 14) 𝑃
Gender (m) 28 4 0.370
Tremor subtype 34 7 0.977
Hallucinations (𝑛 = 4) 4 1 1.000
FAB < cut-off (𝑛 = 17) 17 9 0.014∗
MMSE < cut-off (𝑛 = 6) 4 2 0.638
Age 71.9 ± 7.53 75.4 ± 4.55 0.099
Age of onset 69.1 ± 7.76 72.7 ± 4.75 0.098
Duration 2.8 ± 1.40 2.7 ± 1.27 0.891
Education 4.4 ± 4.22 4.1 ± 3.46 0.858
HY stage 1.8 ± 0.59 1.8 ± 0.54 0.845
DED 390.0 ± 355.80 487.5 ± 695.49 0.453
UPDRS total 18.6 ± 11.05 15.5 ± 13.92 0.374
Dysarthria 0.6 ± 0.75 0.6 ± 0.75 0.987
Tremor 4.1 ± 3.71 4.1 ± 4.37 0.946
Rigidity 2.3 ± 3.07 1.7 ± 1.20 0.551
Bradykinesia 7.4 ± 6.19 5.8 ± 6.73 0.377
Gait/posture 1.4 ± 1.14 1.6 ± 1.28 0.609
Values are mean ± standard deviation, except for categorical variables.
a measure of change: score at 𝑡
1
− score at 𝑡
0
. Paired









) were compared by means of McNemar’s tests.
In a second analysis, we studied the relation between cog-
nitive tests scores and clinical variables at 𝑡
0
and the presence
of cognitive decline at 𝑡
1
. Predictor variables (independent
variables) were UPDRS total score, bradykinesia, rigidity,
tremor, speech, gait-posture scores, Hoehn and Yahr scores,
age, age of onset, diration of disease, education, gender, DED,
global cognitive dysfunction, frontal cognitive dysfunction
and presence of hallucinations. Outcome variables (depen-
dent variables) were dementia at 𝑡
1
, change in the MMSE,
and change in the FAB. To test the relation between predictor
and outcome variables, the former were dichotomized at
the median. Fisher’s exact test was used to test the rela-
tion between predictor variables and dementia, and Mann-
Whitney tests were used to test the relation between predictor
variables and the MMSE and FAB change. Multivariate
analysis was not performed, either because there were few
positive cases (dementia) or because few variables were found
as significant predictors (FAB and MMSE change).
In a third analysis, we aimed at evaluating clinical het-
erogeneity in the early stages of Parkinson’s disease and its
influence on cognitive decline. A two-step cluster analysis
was performed, in which we entered all predictor variables.
Differences between the clusters thus formed were tested by
means of two-samples 𝑡-tests or chi-square tests.
3. Ethics
Patients signed informed consent forms, and the ethics com-
mittee of the institution approved the protocol.
4. Results
Of the 75 patients assessed at 𝑡
0
, 61 were reassessed at 𝑡
1
.
Fourteen were not reassessed: 2 died from causes unrelated
to PD; 1 refused reassessment; diagnosis changed in 4, which
at follow-up were found not to have PD; 7 patients were
out of contact and were lost for follow-up. Dropouts showed
a tendency for older age and older age of onset. Frontal
dysfunction was significantly more frequent in this group.
There were no other significant differences in demographic,
motor, or cognitive variables between patients lost for follow-
up and the rest of the cohort (Table 1).
At 𝑡
0
, no patient was demented against 4 at 𝑡
1
(incidence
of 33.9/1000 per year). The patients with global cognitive




(𝑛 = 6). The MMSE
scores decreased in 23 patients (mean change −1.91 ± 1.20,
range from −1 to −5), increased in 21 patients (mean change
1.81 ± 0.98, range from 1 to 5), and did not change in
17 patients. The frequency of frontal cognitive dysfunction
increased from 26 to 32, but the difference did not reach
significance (𝑃 = 0.201). The FAB scores decreased in 29
patients (mean change −2.04 ± 1.37, range from −1 to −5),
increased in 23 patients (mean change 2.87±1.74, range from
1 to 7), and did not change in 9 patients.
There were no significant variations in the MMSE total
and subscores (Table 2).
Changes in the FAB were significant for lexical fluency
task (lower at 𝑡
1
) (Table 3).
Table 4 shows the relation between predictive variables at
𝑡
0
and the occurrence of dementia. Higher speech, rigidity,
gait/posture scores, and the presence of hallucinations and
of the nontremor phenotype were significantly related to
dementia.
Table 5 shows the relation between variables at 𝑡
0
and
the changes in the MMSE and FAB scores. Frontal cognitive
4 Parkinson’s Disease






Total score 27.20 (2.544) 27.11 (2.745) −0.098 (4%) 0.678
Orientation 9.59 (0.844) 9.48 (0.924) −0.115 (1%) 0.289
Registration 3.00 3.00 0
Attention and calculation 4.00 (1.252) 4.07 (1.276) 0.066 (2%) 0.636
Recall 2.31 (0.720) 2.39 (0.737) 0.082 (4%) 0.450
Language 7.62 (0.522) 7.67 (0.598) 0.492 (1%) 0.496
Visuoconstructive ability 0.66 (0.479) 0.54 (0.502) −0.115 (17%) 0.090
Values aremean standard deviation ormean variation (percent variation). Negative valuemeans decrease from 𝑡0 to 𝑡1.𝑃 value is significance for paired sample
student’s 𝑡-tests. Registration scores remained constant throughout the study.






Total 11.20 (2.971) 11.30 (3.309) 0.115 (1%) 0.738
Similarities 0.90 (0.810) 0.87 (0.826) −0.033 (4%) 0.766
Lexical fluency 1.93 (0.873) 1.72 (0.968) −0.213 (11%) 0.022∗
Motor series 2.15 (0.946) 2.25 (0.925) 0.0984 (4%) 0.451
Conflicting instructions 1.77 (1.131) 1.92 (1.187) 0.1475 (8%) 0.268
Go-No Go 1.51 (0.868) 1.56 (1.009) 0.0492 (3%) 0.717
Prehension behaviour 3 3 0
Values aremean standard deviation ormean variation (percent variation). Negative valuemeans decrease from 𝑡0 to 𝑡1.𝑃 value is significance for paired sample
student’s 𝑡-tests. Prehension behaviour scores remained constant throughout the study. ∗𝑃 < 0.05.
Table 4: Baseline comparisons between the PD patients with and
without dementia.
Dementia
Yes (𝑛 = 4) No (𝑛 = 57) 𝑃
Gender (m) 2 (50.0) 26 (45.6) 1.000
Tremor subtype 0 (0) 34 (59.6) 0.034∗
Hallucinations 2 (50.0) 2 (3.5) 0.019∗
FAB 3 (75.0) 14 (40.0) 0.303
MMSE 3 (75.0) 3 (5.3) 0.002∗∗
Age > 72 4 (100) 28 (49.1) 0.114
Age of onset > 69 4 (100) 29 (50.9) 0.118
Duration > 2 2 (50) 29 (50.9) 1.000
Education > 3 2 (50) 33 (57.9) 1.000
HY stage > 1 4 (100) 36 (63.2) 0.289
DED > 395 4 (100) 29 (50.9) 0.118
UPDRS total > 16 4 (100) 29 (50.9) 0.118
Speech 4 (100) 25 (43.9) 0.046∗
Tremor > 4 2 (50) 17 (29.8) 0.582
Rigidity > 1 4 (100) 24 (42.1) 0.039∗
Bradykinesia 4 (100) 26 (45.6) 0.053
Gait/posture > 1 4 (100) 25 (43.9) 0.046∗
Values are number of patients (percentage). 𝑃 value is significance for chi-
square statistics. ∗𝑃 < 0.05, ∗∗𝑃 <= 0.01.
dysfunction and higher education were significantly related
to the decreases in the MMSE scores. As chi-square analysis
revealed that these two variables were significantly correlated
(frontal dysfunction being more frequent in patients with
higher education: 57.1% versus 23.1%, 𝑃 = 0.010), they were
included as predictor variables in a linear regression analysis
model, with the MMSE variation as an outcome variable.
This showed that only frontal dysfunction had a significant
influence in the MMSE variation (𝑏 = 1.37, 𝑃 = 0.003).
Higher rigidity and speech scores were significantly
related to the decreases in the FAB scores (Table 5).
Cluster analysis yielded two clusters. Compared to
patients in cluster 2 (𝑛 = 35), cluster 1 (𝑛 = 26) patients
presented with significantly higher HY stage (𝑃 < 0.00001),
UPDRS total score (𝑃 < 0.00001) dysarthria (𝑃 < 0.00001),
tremor (𝑃 = 0.019), rigidity (𝑃 = 0.004), bradykinesia
(𝑃 < 0.00001), gait and postural instability (𝑃 < 0.00001)
scores, and a significantly higher prevalence of the nontremor
phenotype (𝑃 < 0.00001). Patients with hallucinations were
all included in cluster 1 (𝑃 = 0.029). Patients in cluster 1
showed a more significant decrease in the FAB scores (𝑃 =
0.040). Patients who subsequently developed dementia were
all included in cluster 1 (𝑃 = 0.029).
5. Discussion
5.1. Variation of the MMSE and FAB Scores over Time.





nonsignificant. Mean change was lower than in previous
studies [35, 37, 38] and closer to that of Gago et al. [20]
and of Williams-Gray et al.’s [39] studies, who also evaluated
early stage patients. A slower rate of decline in the first stages
of disease is in accordance with Aarsland et al. study [38]
that has shown a nonlinear pattern of decline in the MMSE,
with an inflection point at about 11 years duration, beyond
which decline was steeper, reaching a mean of 2.8 points
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) MMSE change FAB change
Mean variation 𝑃 Mean variation 𝑃
Gender
Male −0.21 (1.75) 0.871 −0.21 (3.05) 0.244
Female 0.69 (1.93) 0.39 (2.30)
Motor subtype
Tremor 0.00 (1.46) 0.842 0.50 (2.34) 0.186
Nontremor −0.22 (2.26) −0.30 (2.98)
Hallucinations
Yes 0.00 (4.40) 0.965 0.50 (1.43) 0.680
No −0.10 (1.67) 0.12 (2.54)
Frontal dysfunction
Yes −0.88 (2.27) 0.002∗∗ 0.46 (2.85) 0.474
No 0.49 (1.17) −0.09 (2.51)
Global cognitive dysfunction
Yes 0.00 (3.69) 0.980 −0.83 (2.04) 0.207
No −0.11 (1.58) 0.25 (2.70)
Age
72 0.09 (2.27) 0.239 0.41 (2.84) 0.296
≤72 −0.31 (1.23) −0.21 (2.47)
Age of onset
69 0.18 (2.21) 0.072 0.52 (2.84) 0.247
≤69 −0.43 (1.23) −0.28 (2.39)
Duration
2 −0.58 (1.88) 0.080 −0.48 (2.74) 0.077
≤2 0.40 (1.69) 0.80 (2.43)
Education
3 −0.46 (1.62) 0.048∗ −0.03 (2.57) 0.723
≤3 0.38 (2.04) 0.31 (2.83)
HY stage
1 −0.95 (1.76) 0.914 −0.28 (2.57) 0.051
1 −0.10 (1.91) 0.95 (2.67)
DED
395 0.04 (1.40) 0.819 0.68 (2.39) 0.101
≤395 −0.21 (2.16) −0.36 (2.83)
UPDRS total
>16 −0.03 (1.31) 0.507 −0.15 (2.86) 0.160
≤16 −0.18 (1.31) 0.43 (2.42)
Speech
>0 −0.10 (2.19) 0.774 −0.55 (2.96) 0.022∗
0 −0.10 (1.49) 0.78 (2.20)
Tremor
>4 −0.37 (2.57) 0.471 0.37 (2.64) 0.671
≤4 0.02 (1.42) 0.05 (2.68)
Rigidity
>1 −0.21 (2.13) 0.586 −0.54 (2.49) 0.020∗
≤1 0.00 (0.16) 0.73 (2.68)
Bradykinesia
>7 −0.13 (2.19) 0.978 −0.03 (2.66) 0.350





) MMSE change FAB change
Mean variation 𝑃 Mean variation 𝑃
Gait/posture
>1 −0.25 (1.70) 0.471 −0.28 (3.03) 0.111
≤1 0.07 (2.00) 0.53 (2.23)
Values are mean standard deviation. 𝑃 value is significance for Mann-Whitney tests.
annually. More recently, Lessig et al. [40] also found that
the MMSE variation was more pronounced after the first 10
years of disease. A third of the patients presented a decline
in the MMSE total scores. Improvement in other patients,
however, compensated these changes, resulting in almost null
mean variation over time. Although the short time interval
between evaluations may have promoted a learning effect,
contributing to an improvement on follow-up assessment, the
different pattern of cognitive change could argue in favor of a
heterogeneous progression of neuropsychological deficits in
the early stages of PD. It also suggests that theMMSEmay not
be indicated for detecting cognitive change at these stages of
disease, which could require more demanding measures of
cognitive dysfunction. Frontal dysfunction progression was
also heterogeneous. Significant variations occurred only in
relation with lexical fluency, suggesting that this could be
fit to measure cognitive changes at these stages of disease.
Significant progression in lexical fluency deficits was also
found by Azuma et al. [41] and Levy et al. [42].
5.2. Predictors of Dementia. Only four patients presented
dementia at follow-up (annual incidence 33.9/1000). Inci-
dence was lower than in most studies, in which this figure
ranged from 30 to 107/1000 [38, 43, 44]. This could be due
to the specific nature of our cohort, which was constituted
only by early stage disease patients and also to the relatively
short follow-up time. Previouswork has shown that dementia
incidence increases as the disease progresses, and the lower
values are found in studies performed in early stage patients
[45]. This is also in accordance with the wide believed notion
that dementia is a late finding in PD.
Nontremor motor scores, nontremor motor phenotype,
the presence of hallucinations, and scores below cut-off in
the MMSE were related to dementia at follow-up. Significant
relation between hallucinations and cognitive dysfunction
in PD has been found in several studies [46, 47]. Non-
demented PD patients with hallucinations show significant
atrophy in frontal and occipitotemporal cortical regions
whose progression was linked to cognitive deterioration in
longitudinal studies [47], meaning that hallucinations could
be a sign of early neuropathological changes leading to
dementia in the long run. Nontremor motor phenotype was
significantly more frequent in patients that subsequently
developed dementia, as also found in previous longitudinal
studies [48]. Axial motor dysfunction, like gait and speech
disturbances, responds poorly to dopaminergic treatment,
and some authors have proposed that cholinergic dysfunction
could contribute to these symptoms. PD dementia has also
been associated with cholinergic rather than dopaminergic
deficits, and some have suggested that dementia and gait
dysfunction could have the same physiopathological basis,
originating from cholinergic deficits caused by pedunculo-
pontine andof nucleus basalis theMeynert degeneration [42].
Previous work has suggested that theMMSE could be less
sensitive to mild cognitive impairment, when compared to
frontal oriented tests, like the Montreal cognitive assessment
scale [13–15], although it is better for tracking cognitive
changes over time in PD [32]. Our data suggests that the
MMSE, and particularly the cut-off values, determined in the
validation study of the Portuguese version of the test, could
be useful for predicting PD dementia in early stage patients.
The presence of cognitive deficits in patients that eventually
develop a state of full-blown dementia suggests that cognitive
dysfunction is a progressive disorder in PD, and that demen-
tia, as happens withAlzheimer’s disease, is preceded by a state
of subtler neuropsychological dysfunction, compatible with
the notion of mild cognitive impairment.
Contrary to the MMSE scores, the FAB scores were not
useful in predicting dementia. This could be related to the
nature of cognitive deficits in PD-related dementia. Previous
investigation has shown a significant relation between the
progression to dementia and the superimposition of non-
frontal deficits in patients with frontal deterioration [49]. In
this way, a global, non-frontal test could be more helpful to
predict dementia than a frontal-oriented one.
5.3. Predictors of Global and Frontal Cognitive Decline. No
variable was predictive of a decline in the MMSE, except
for the presence of frontal dysfunction. Although our data
does not allow for a straightforward explanation for these
findings, we could hypothesize that, frontal dysfunction
being the first step in PD-related cognitive deterioration,
as mentioned above, it could act as a predictor in some
patients of widespread decline of cognitive function. On the
other hand, some studies [24, 25] have found significant
correlations between FAB and MMSE, which could have
biased our results.
Similar to dementia, frontal dysfunction was predicted
by nontremor motor symptoms, although the pattern was
slightly different. In particular, patients with higher gait and
postural dysfunction scores at baseline did not present a
greater decline in the FAB scores. As previously discussed,
gait dysfunction seems to be mostly correlated to cholin-
ergic rather than to dopaminergic deficits. Other authors
found an association between executive dysfunction and
dopamine responsive symptoms, while cortical posterior
deficits were associated with dopamine resistant symptoms
[49]. Williams-Gray and coworkers [39] have found that
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the frontal type deficits at the early stages of disease are
not related to dementia at follow-up but to COMT gene
mutations, that is, to dopamine dysfunction. They hypoth-
esized that there could be a dissociation between frontal/
dopaminergic related dysfunction, bearing no relation with
dementia at follow-up, and MAPT/ageing/posterior type of
cognitive deficits, which could be predictive of dementia.
The relation between PD-related dementia and cholinergic
dysfunction could explain the improvement of cognitive
function in PD patients treated with cholinesterase inhibitors
2.
5.4. Cluster Analysis. Cluster analysis showed two groups
that differed regarding the presence of hallucinations and
the severity of nontremor motor symptoms. The cluster
with worse nontremor symptoms and hallucinations showed
a steeper progression of frontal dysfunction and a higher
prevalence of dementia, which is in accordance with results
from the previous analysis. Comparison with other studies
is difficult, because cluster analysis depends on the variables
that are included. However, Erro and collaborators [5] did
find a cluster in which worse axial motor symptoms are
correlatedwithworse outcome. Lewis et al. also found a group
with worse nontremormotor symptoms and significant levels
of cognitive impairment [6].
The present study has several limitations, which should
be taken into account when discussing the data. Because we
assessed an early stage cohort, and the follow-up time was
relatively short, the ratio of dementia conversation was very
low. This prevents multivariate analysis procedures, weakens
the statistical analysis, and precludes definite conclusions
regarding the predictive factors for dementia in this group.
Patients were recruited from a tertiary centre outpatient
clinic, and the sample was small, precluding the generaliza-
tion of results to an epidemiological level—it does, however,
mirror the clinical experience of a Portuguese neurological
center and could be informative in that context.
In conclusion, our data suggests that nontremor motor
deficits are predictive factors for dementia and frontal type
decline in the early stages of Parkinson’s disease. They also
suggest that mini-mental state examination cut-off scores
could be useful for predicting dementia in these stages.
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